# Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

> **NCT01864174** · PHASE4 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1736 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Metformin XR
- **DRUG:** Metformin IR
- **DRUG:** Placebo matching with Metformin XR
- **DRUG:** Placebo matching with Metformin IR

## Key facts

- **NCT ID:** NCT01864174
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-20
- **Primary completion:** 2016-06-01
- **Final completion:** 2016-06-01
- **Target enrollment:** 1736 (ACTUAL)
- **Last updated:** 2019-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01864174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01864174, "Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01864174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*